Disruptive purification consumables for the pharmaceutical industry

Project Information

Separative

Grant agreement ID: 815526

DOI

10.3030/815526

Project closed

EC signature date 16 May 2018

Start date 1 March 2018

End date 31 July 2018

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 71 429,00

EU contribution

€ 50 000,00

Coordinated by

SEPARATIVE
France

Periodic Reporting for period 1 - Separative (Disruptive purification consumables for the pharmaceutical industry)

Reporting period: 2018-03-01 to 2018-07-31

Summary of the context and overall objectives of the project

SEPARATIVE is a French startup developing consumables for purification by chromatography thanks to a ground-breaking multicapillary material and the related manufacturing process, both protected by four patents. It is the first innovation for several decades that disrupts the state-of-the-art high-pressure constraints of the High-Performance Liquid Chromatography (HPLC), and that achieves chromatographic purification and analysis without the inherent high-pressure and high-cost. SEPARATIVE allows to offer reusable low-pressure HPLC columns and reduces the cost of current chromatography by a factor of 10-50 (depending on the application).
The technology was validated by an independent laboratory. The manufacturing process internally developed and assessed, including an industrial pilot plant, demonstrated some strong productivity and cost-effectiveness potential. On this basis, the industrialization was the next step to ensure the reproducibility of the manufacturing, reach the market performances expectations, and make the process scalable.
The SME Phase 1 involved an industrialization study including an automation study, a value chain organization analysis and a marketing mix review.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

The outcomes of the work plan include the technical solutions and the roadmap toward the process automation, a better knowledge of the supplier landscape and the identification of the partners needed, and a comprehensive marketing mix definition that give SEPARATIVE’s team strong confidence in the way to carry out the future beta testing program.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The progresses achieved are critical for the following of the project. They include some decisive development as much from the business point of view as the production end :
- a more accurate knowledge of the market expectations,
- the automation of the key steps of the manufacturing process,
- the definition of the control process,
- the design of the next version of the pilot plan,
- the selection of the key suppliers.
The expected results are the industrialization validation and the gathering of the expected conditions to initiate an optimization program of the product to improve its performances.
Bringing the product to the market will provide several technological advantages to the healthcare industry: better quality of drugs due to higher purity, lower investments for production plants (savings of 59% for separation), lower manufacturing costs due to better yields (no losses of valuable material in process) and higher security of manufacturing process due to lower volumes of flammable and toxic solvents.

Logo Separative